Janus Henderson Group PLC purchased a new position in Glaukos Corporation (NYSE:GKOS) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,119,256 shares of the medical instruments supplier’s stock, valued at approximately $129,356,000. Janus Henderson Group PLC owned 9.06% of Glaukos Corporation at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GKOS. Great West Life Assurance Co. Can purchased a new stake in Glaukos Corporation in the 1st quarter valued at approximately $102,000. BNP Paribas Arbitrage SA lifted its stake in Glaukos Corporation by 740.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 3,118 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Glaukos Corporation in the 1st quarter valued at approximately $204,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Glaukos Corporation in the 2nd quarter valued at approximately $262,000. Finally, Caxton Associates LP purchased a new stake in Glaukos Corporation in the 1st quarter valued at approximately $272,000.

A number of equities research analysts recently issued reports on GKOS shares. BidaskClub raised Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised Glaukos Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Roth Capital reduced their target price on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $49.86.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/3119256-shares-in-glaukos-corporation-gkos-purchased-by-janus-henderson-group-plc/1619696.html.

Shares of Glaukos Corporation (NYSE:GKOS) traded down 2.65% on Monday, hitting $32.70. The company’s stock had a trading volume of 74,309 shares. The stock’s 50 day moving average is $34.14 and its 200-day moving average is $34.14. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49. The company’s market cap is $1.13 billion.

In related news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc sold 580,200 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 980,200 shares of company stock worth $37,900,263. 16.40% of the stock is owned by insiders.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.